#United States #California #Class Action #ChemoCentryx #Settlement

ChemoCentryx Securities Litigation Proposed Settlement

In a significant development for shareholders of ChemoCentryx, Inc., a proposed settlement has been announced in the ongoing securities class action suit known as Homyk v. ChemoCentryx, Inc., pending in the Northern District of California. This legal matter, rooted in allegations against the company and its former CEO, may see a resolution through a substantial monetary settlement of $69 million.

Background of the Case

The class action lawsuit stems from claims made by the Indiana Public Retirement System, representing shareholders who purchased ChemoCentryx stock between November 26, 2019, and May 6, 2021. The allegations assert that during this period, the defendants made misleading statements regarding critical developments related to the company’s clinical trials and communications with regulators concerning the approval of avacopan, a drug tested by ChemoCentryx. These alleged misrepresentations are cited as direct violations of federal securities laws, specifically Section 10(b) of the Securities Exchange Act of 1934.

The plaintiffs argue that the defendants, including Dr. Thomas J. Schall, engaged in actions that misled investors about the viability and approval processes related to avacopan, consequently impacting the stock's value and shareholders' investments. ChemoCentryx officials categorically deny all allegations, asserting that there was no wrongdoing involved in their procedures or communications.

Settlement Hearing Scheduled

A hearing to discuss the proposed settlement has been scheduled for October 29, 2026, at 2:00 PM Pacific Time. This will take place via Zoom videoconference, presided over by the Honorable Jon S. Tigar. During this hearing, the court will evaluate whether the settlement is fair and reasonable, consider the dismissal of the case with prejudice against the defendants, and discuss the proposed plan for distribute the settlement funds to eligible class members.

As part of the agreement, class counsel is permitted to request attorney fees not exceeding 22% of the settlement fund and reimbursement of litigation costs up to $5 million. These financial elements will also be assessed during the hearing.

Actions for Class Members

Members of the class are encouraged to stay informed as their rights will be directly affected by this proposed settlement. Class members who wish to participate in the settlement must submit a claim form no later than October 1, 2026. Failure to submit this form will result in an inability to receive any potential payment from the settlement, although affected individuals will still be bound by court judgments.

Any objections to the settlement, allocation plans, or attorney fees must be filed with the court by September 21, 2026. Class members previously given the opportunity to opt-out will not have a second chance; however, those who opted out may choose to rejoin the class by following specific instructions outlined in the settlement notice.

For further information regarding claims and to confirm participation in the hearing, class members can visit the dedicated case website at www.ChemoCentryxSecuritiesLitigation.com.

Final Thoughts

The proposed $69 million settlement represents a pivotal moment for investors in ChemoCentryx, potentially providing a financial remedy for losses incurred during the stated class period, amidst a backdrop of legal complexities surrounding corporate communications and market integrity. As the scheduled hearing approaches, stakeholders will be watching closely, eager for the court’s decision regarding the settlement’s approval and the future of this litigation.